The greens-powder aisle runs on a simple promise: a scoop, a capsule or a gummy standing in for the produce you did not eat. Powdered blends of fruit, vegetable and berry concentrates are sold as convenience, insurance, or both, and the category has grown faster than the evidence behind it.

On 22 August, Nutrients published a six-month randomized controlled trial of one such product in older adults. It is the kind of study the category has been missing, and its own authors are careful about what it shows. Reading it closely is a useful exercise, because the design answers a narrower question than the marketing does.

What the study set out to measure

The trial, run through the Medical University of Graz in Austria, randomised generally healthy adults aged 55 to 80 — postmenopausal women and men, non-smokers, body-mass index between 18.5 and 40 — to a control group of 16 or an intervention group of 18. Everyone in the study ate fewer than four servings of fruit and vegetables a day to qualify, and the food diaries kept at baseline recorded an average of under two servings a day in both groups.

The intervention group took six capsules daily of an encapsulated fruit, vegetable and berry juice concentrate, about 4.9 grams of powder drawn from 36 fruits, vegetables and berries. Those six capsules supplied, by the authors’ analysis, 158 mg of vitamin C, 316 µg of folic acid, 1.46 mg of vitamin A in retinol activity equivalents, 18.65 mg of alpha-tocopherol equivalents, 6.1 mg of lutein and 1 mg of lycopene, plus roughly 600 mg of polyphenols. The control group kept its habitual diet and took no supplements.

The trial is larger than the paper: it has four arms and a planned enrolment of 80, and it is designed to run for 12 months. This publication reports the pre-specified six-month timepoint for two of those arms only.

Crucially, the primary outcome was metabolic safety — liver, kidney, thyroid, lipid and glucose markers — not any measure of health benefit. Markers of oxidative stress and cardiovascular risk were classified as exploratory.

What six months of capsules did to safety markers

On the safety question, the answer was unremarkable in the way a safety study hopes to be. No severe or product-related adverse events were reported, adherence ran at about 90% by capsule count and was corroborated by a rise in plasma vitamin C, and every measured value stayed inside its laboratory reference range.

Within-group movements did occur. Aspartate aminotransferase fell in the supplement group from 28.50 to 24.94 U/L (p = 0.008), while alkaline phosphatase rose in the control group from 72.06 to 76.81 U/L (p = 0.036) and urea rose in the control group from 27.38 to 30.44 mg/dL (p = 0.044). The authors read these as expected age-related drift rather than product effects, and note that none of the shifts crossed into clinical relevance.

The exploratory findings, and the adjustment that changed them

The attention-grabbing numbers sit in the exploratory layer, and they behave the way exploratory numbers often do.

Carbonyl proteins, a marker of protein oxidation, fell by roughly 20% in the supplement group, from 87.60 to 69.98 U/mL, with a significant time-by-group interaction (p = 0.030). Once the analysis was adjusted for baseline values, age and body-mass index, the between-group difference dropped to p = 0.097 — a trend, not a result. Two other oxidative-stress markers, malondialdehyde and oxidised LDL, showed no change at all.

Homocysteine held steady in the supplement group while rising in the control group, from 10.78 to 11.97 µmol/L (p = 0.006). This was the most durable finding in the paper: the interaction was significant at p = 0.002 and the adjusted between-group difference at p < 0.001, with adjusted means of 11.57 versus 9.29 µmol/L.

Blood pressure produced the split result that tends to get flattened in coverage. Systolic pressure fell within the supplement group from 144.24 to 136.59 mmHg (p = 0.018), but after adjustment the between-group difference was no longer significant (p = 0.139). Diastolic pressure did not change significantly within the supplement group on its own (p = 0.058), yet its interaction was significant (p = 0.011) and it survived adjustment (p = 0.015). The baseline averages sat in what the authors describe as grade 1 hypertension territory, which makes the readings worth watching and also worth treating cautiously in a group this small.

Four reasons to read the result narrowly

The paper is candid about its limits, and they matter more than the p-values.

  • It is one product, not the category. Six capsules of a specific multi-ingredient concentrate are not interchangeable with an unrelated powder, a gummy or a juice shot. The authors state plainly that because the supplement is multi-ingredient, none of the observed effects can be tied to a single compound.
  • The trial was not powered for these endpoints. Sample-size calculations for the full study were based on the omega-3 index and TNF-alpha, and 20 participants per arm were planned. The six-month comparison of 16 and 18 people was explicitly described as exploratory.
  • It was open-label. Participants and investigators knew who was taking what. The outside laboratory analysing safety markers and homocysteine received coded samples, but the in-house oxidative-stress measurements were not blinded.
  • Industry is close to the work. Two authors are affiliated with the Green Beat Institute of Nutrient Research, which coordinated randomisation, and the limitations section notes that the study was conducted by the institute that received funding from the study sponsor.

The authors’ own conclusion is that the findings are “hypothesis-generating rather than confirmatory” and require confirmation from the complete trial. That is the correct reading. A safe six-month run in 34 people is reassurance about tolerability. It is not evidence that a powder delivers the benefits of produce.

What the label does and does not guarantee

Greens powders are sold as dietary supplements, a category with a particular regulatory shape. As the FDA puts it in its consumer guidance, the agency “does NOT have the authority to approve dietary supplements for safety and effectiveness, or to approve their labeling, before the supplements are sold to the public.”

The NIH’s National Center for Complementary and Integrative Health adds two practical cautions: supplements bought in stores or online “may differ in important ways from products tested in research studies,” and what is listed on a label may not be what is in the product. The center also flags interactions with medications, risks around surgery, and the thin evidence base for many products.

Dose arithmetic is worth doing on any concentrated product. The six capsules in this trial supplied 158 mg of vitamin C. MedlinePlus lists the recommended dietary allowance for adults 19 and older at 90 mg a day for men and 75 mg for women, and notes that intakes above 2,000 mg a day are not recommended. A supplement can therefore push a nutrient well past the recommended intake without resembling a serving of produce — a point we examined in our look at the fibre gap and supplement shortcuts.

The comparison the category invites

The reason people buy these products is the produce they are not eating, so the relevant evidence is the evidence on produce. Harvard’s Nutrition Source is direct about the underlying logic: “No single fruit or vegetable provides all of the nutrients you need to be healthy.”

The cohort data behind that guidance is substantial. A meta-analysis of studies following 469,551 participants found higher fruit and vegetable intake associated with a lower risk of death from cardiovascular disease, averaging a 4% reduction per additional daily serving. In Harvard’s own cohorts, people averaging eight or more servings a day were 30% less likely to have had a heart attack or stroke than those averaging fewer than 1.5. Those are observational associations, not trial results, and they describe dietary patterns rather than capsules.

That distinction is the whole story here. A supplement trial can show that a product is tolerated, and this one does. Whether a powder changes the things people actually care about — heart attacks, strokes, death — has not been tested, and a six-month run of surrogate markers in 34 volunteers cannot get there. If you are among the many people who eat less produce than they intend, the signs of a vegetable shortfall are a more useful starting point than the supplement shelf.

None of this is a reason to panic about a product, and none of it is medical advice. Supplements can interact with prescription medicines and may carry risks around surgery or pregnancy, so the sensible move is to raise any supplement you are taking — including a greens powder — with a pharmacist or clinician who knows your history. Our medical disclaimer explains how we draw the line between reporting evidence and advising individuals.